GlassScriptPhysician profile
Travis J Nelson
NPI 1386985869
$3,801.87
in general payments reported to CMS, 2019-2025
23 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.59 · 2023: $377 · 2024: $1,459 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $958.53 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $411.95 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $411.43 | 2023-2025 | |
| Pfizer INC. | $332.63 | 2023-2025 | |
| Lilly USA, LLC | $290.85 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $273.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.44 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.71 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $115.85 | 2024-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $115.09 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $77.52 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biogen, INC. | $70.59 | 2022 | |
| Amgen INC. | $61.90 | 2023-2025 | Repatha, Otezla, Otezla |
| Electromed, INC. | $60.07 | 2025 | Smartvest |
| Mylan Specialty L.P. | $56.79 | 2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.18 | 2023-2024 | Trintellix |
| Dexcom, INC. | $44.39 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $41.94 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.94 | 2025 | Caplyta |
| Organogenesis INC. | $19.78 | 2023 | Puraply |
| Axsome Therapeutics, INC. | $18.26 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $14.96 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $7.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.